AVACTA GRP. ORD 10P news, videos and press releases
For more news please use our advanced search feature.
AVACTA GRP. ORD 10P - More news...
AVACTA GRP. ORD 10P - More news...
- Avacta Reports Pipeline Advances with Two Novel Programs at the EORTC-NCI-AACR Molecular Targets Symposium in Barcelona
- Avacta and Tempus Enter Strategic Collaboration to Advance AI-Driven Drug Development in Oncology
- Avacta Expands its Pipeline with Two Novel Assets Developed Using its pre|CISION® Platform
- Avacta Group strengthens executive team with appointment of Michelle Morrow, PhD as Chief Scientific Officer
- Avacta Group strengthens executive team with appointment of Michelle Morrow, PhD as Chief Scientific Officer
- Avacta to Unveil Pipeline Expansion and Novel, Next-Generational Targeted Cancer Therapy Programs at 2024 EORTC-NCI-AACR Symposium
- Avacta to Unveil Pipeline Expansion and Novel, Next-Generational Targeted Cancer Therapy Programs at 2024 EORTC-NCI-AACR Symposium
- Avacta Reports Updated Phase 1 Clinical Data of AVA6000 at the European Society for Medical Oncology (ESMO) Congress Demonstrating Multiple Ongoing, Durable Responses in Solid Tumors
- Avacta to present updated clinical data on AVA6000 at the European Society for Medical Oncology (ESMO) Congress
- Avacta Announces the Appointment of Darlene Deptula-Hicks as Non-Executive Director of the Board of Directors
- Avacta Group - AVA6000 Abstract Release by AACR and Full Presentation Update
- Updated Results from Single-Agent Phase 1 Clinical Trial of Peptide Drug Conjugate, AVA6000 to be Presented in a Poster at the American Association of Cancer Research (AACR) Annual Meeting on April 9, 2024
- Appointment of Chief Business Officer
- ALS-6000-101 Phase 1a Three-Weekly Dose Escalation Safety Study Data
- Avacta to present promising new data from Affimer® and pre|CISIONTM platform assets at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
- Avacta Announces Successful Completion of Fifth Dose Escalation in AVA6000 Phase 1 Clinical Study
- First Patient Dosed in the US in Avacta’s AVA6000 Phase 1 Clinical Study
- Avacta Appoints Karen Harrison as Chief Operating Officer for Therapeutics Division
- Avacta Announces AVA6000 Receives Orphan Drug Designation From the US Food and Drug Administration
-
Avacta receives more support after cancer drug progress 🤞
- LG Chem Renews License Triggering Payment to Avacta
-
Avacta push ahead with cancer treatment
- Avacta Announces AffyXell Joint Venture Milestone and Increased Equity Stake
- Avacta Appoints Dr Christina Coughlin as Non-Executive Director
- Avacta Announces Dose Escalation in the Phase I Clinical Study of AVA6000 Pro-doxorubicin
- Avacta Selects Second pre|CISION™ Pro-drug Candidate for Development
- Avacta Announces AffiDX® SARS-CoV-2 Antigen Lateral Flow Test Receives CE Mark for Consumer Self-Testing
- Avacta Announces AffiDx® SARS-CoV-2 Antigen Lateral Flow Test Detects the Omicron Variant
- Avacta Announces FDA Approval of its Investigational New Drug (IND) Application for AVA6000
- Avacta Announces First Patient Dosed in AVA6000 Pro-Doxorubicin Phase I Clinical Trial
